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Instillation therapy with attenuated tuberculosis bacteria (BCG) can signiﬁcantly reduce rates of recur-
rence of non-muscle invasive bladder cancer. Local and systemic side effects such as dysuria, irritative
voiding symptoms or partial bladder contracture and systemic inﬂammation were reported. A 75 year-
old male patient with recurrent non muscle invasive bladder cancer developed necrosis of the entire
bladder urothelium more than six years after BCG instillation immunotherapy. The resulting irritative
voiding symptoms and low bladder capacity required radical cystectomy. BCG instillation can cause
severe side effects, which develop gradually and eventually need radical surgical therapy such as cys-
tectomy without tumor recurrence.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Urothelial cancer of the bladder is the sixth most common
cancer with an estimated 74,000 newly diagnosed cases in 2014. It
can be divided into non muscle invasive (NMIBC: pTa, pT1 and
carcinoma in situ (CIS), 86% of the patients) and muscle invasive
bladder cancer (MIBC: >pT2, 14% of the patients) with worse
prognosis of the latter. MIBC requires open surgical therapy such as
cystectomy with urinary diversion and often adjuvant chemo-
therapy. NMIBC is treated by an initial transurethral resection (TUR)
and in case of intermediate or high risk tumors by adjuvant intra-
vesical instillation chemotherapy or immunotherapy. Intermediate
risk is deﬁned as multifocal pTa high or solitary T1 tumors and high
risk is deﬁned as multifocal T1 tumors and carcinomas in situ (CIS).
Standard of care for high risk tumors is intravesical instillation of
attenuated tuberculosis bacteria (Bacille Calmette Guerin: BCG),
which is proven to be most effective in reducing the risk of disease
recurrence. BCG induces a cellular and a humoral based immune
reactionwith anti-tumoral effects.1 Localized side effects have been
reported such as abacterial cystitis, dysuria or partial bladder
contracture and systemic side effects such as systemic inﬂamma-
tion (BCGitis) with fever, malaise and sepsis.2 Local side effects candder cancer; MIBC, muscle
.
e (M. Krönig).
Inc. This is an open access article ube treated symptomatically and only require surgical therapy in
case of bladder contracture and ﬁbrosis with reduced bladder
capacitiy.2 Systemic side effects require tuberculostatic treatment.2Case presentation
The patient (male; 75 years) presented with BCG induced uro-
thelial necrosis of the entire bladder, which required cystectomy.
Ten years earlier he was ﬁrst diagnosed with multifocal non-muscle
invasive bladder cancer (NMIBC, transurethral resection (TUR): pT1
G2). A standard second transurethral resection 4weeks later did not
show any remaining tumor. However, 18 and 30 months later he
was diagnosed with recurrent NMIBC (pTa low grade and pTa high
grade/carcinoma in situ (CIS) respectively). Due to the CIS compo-
nent of the tumor the patient received induction therapy with
Bacille Calemette Guerin (BCG) instillations at 31 months. No side
effects were reported. Until 61 months regular cystoscopies did not
show any sign of recurrence. However at 61 months, 30 months
post BCG, the patient ﬁrst reported irritative voiding symptoms and
urine diagnostics showed cells typical for chronic recurrent
inﬂammation but no bacterial infection. A cystoscopy at 62 months
showed ﬁbrin coated old scarrs and the patient continuously re-
ported irritative voiding symptoms and decreasing bladder capac-
ity. At 67 Magnetic Resonance Imaging (MRI) of the pelvis showed
no sign of recurrent tumor or extra vesical disease. The following
transurethral resection showed urothelial necrosis extending into
the muscle layer but no recurrent tumor. In the following monthsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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but no bacterial infection. At 75 months cystoscopy showed ﬁbrin
coated scars covering the entire bladder but no sign of recurrent
tumors. A second MRI showed signal reduced urothelium of the
entire bladder compatible with urothelial necrosis (Fig. 1A). No sign
of tumor growth beneath the necrotic urothelium. Irritative voiding
symptoms of the patient did not improve over the next 2 years.
Follow up did not showany sign of recurrent tumors. At 106months
the cystoscopic ﬁnding has changed from ﬁbrin coated urothelium
to completely dissolving necrotic tissue covering the entire bladder
sparing only the interureteric crest including the ostia (Fig. 1B) (for
complete video see Supporting Information Video S1). This ﬁnding
and the persistently low bladder capacity of the patient required
cystecomy with urinary diversion and ileum neo bladder e nearly
6 years post BCG instillation therapy. Histopathologic analysis of theFigure 1. A) Magnetic Resonance Imaging of the pelvis (axial T1 fs post CM) at 75 months
validation of necrosis of the entire urothelium: Cystoscopy of the patient’s bladder at 75
urothelial necrosis; C) Histological analysis (H&E staining; 20 fold magniﬁcation): extensiv
inﬂammation (arrowheads) as a sign of the former BCG therapy.cystectomy specimen did not show any sign intra- or extravesical
tumor recurrence and conﬁrmed the extensive urothelial necrosis
(Fig. 1C). The patient fully recovered with good continence, normal
bladder capacity and manually assisted voiding.
Discussion
Local or systemic side effects from BCG instillation are reported
frequently and are the main reason for discontinuing therapy.3,4
BCG induced local and systemic side effects were analyzed in
several trials: Brausi et al analyzed 1355 patients for BCG induced
toxicity in different doses and duration of BCG therapy. 30.6% of the
patients were reported with systemic side effects and 60.8% with
local side effects. The most common effects were chemical or bac-
terial cystitis, increased voiding frequency and hematuria. Nopost BCG treatment shows entirely hypoperfused urothelium (arrows); B) Macroscopic
months post BCG treatment months showing a representative section with complete
e necrosis of the urothelium (arrows) and the granulomatous and lympho-follicular
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contracted bladder or necrosis of the urothelium have been re-
ported. Van der Meidjen et al.2 analyzed 487 patients also for BCG
induced toxicity for different treatment durations. Overall 75.2% of
the patients showed local side effects. Contracted bladder was
summarized among others under “other local side effects” and was
reported in 35.7% of the patients. No speciﬁcations were made for
contracted bladder or necrosis of the urothelium. Follow-up was at
least 42 months. A third large trial by Lamm et al.5 analyzed 660
Patients for BCG induced toxicity for different treatment durations
but did not specify side effects in detail. Follow-up was at least
120 months. Orihuela et al4 analyzed 107 patients for BCG induced
toxicity and speciﬁcally reported no bladder contracture or necro-
sis. The above trials show that local side effects are common in BCG
instillation therapy but late onset necrosis of the entire urothelium
as in our case has not been reported yet. Follow up of the above
trials might have been too short to systematically detect such long
term toxicity 6 years post BCG instillation. The history of our patient
shows that sever long term BCG induced side effects exist and even
require radical surgical therapy such as cystectomy without tumor
recurrence.
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